

CM H-26 - Hazardous Drug and Hazardous Waste Lists

| Antineoplastic Hazardous Drugs | | | |
|--------------------------------------|---------------------------|---------------------|-------------------------|
| Drug | Route | Class | Consensus Risk Category |
| Abiraterone | PO | Antineoplastic | |
| Ado-trastuzumab | IV | Monoclonal Antibody | |
| Afatinib | PO | Antineoplastic | |
| Altretamine (capsule) | PO | Antineoplastic | |
| Amsacrine | IV | Antineoplastic | |
| Anastrazole | PO | Antineoplastic | |
| Arsenic trioxide | IV | Antineoplastic | Hazardous Waste |
| Axitinib | PO | Antineoplastic | |
| Azacitidine | IV/SQ | Antineoplastic | |
| Bacillus Calmette-Guerin (BCG) | Intravesical | Anti-Cancer Vaccine | |
| Belinostat | IV | Antineoplastic | |
| Bendamustine | IV | Antineoplastic | |
| Bexarotene | PO | Antineoplastic | |
| Bicalutamide | PO | Anti-androgen | |
| Bleomycin | IV/IM/IP/SQ | Antineoplastic | |
| Blinatumomab | IV | Antineoplastic | |
| Bortezomib | IV/SQ | Antineoplastic | |
| Bosutinib | PO | Antineoplastic | |
| Brentuximab vedotin | IV | Antineoplastic | |
| Busulfan | IV / PO | Antineoplastic | |
| Cabazitaxel | IV | Antineoplastic | |
| Cabozantinib | PO | Antineoplastic | |
| Capecitabine | PO | Antineoplastic | |
| Carboplatin | IV | Antineoplastic | |
| Carfilzomib | IV | Antineoplastic | |
| Carmustine (inj/wafers) | IV/intraventricular | Antineoplastic | |
| Chlorambucil | PO | Antineoplastic | Hazardous waste |
| Cisplatin | IV | Antineoplastic | |
| Cladribine | IV | Antineoplastic | |
| Clofarabine | IV | Antineoplastic | |
| Crizotinib | PO | Antineoplastic | |
| Cyclophosphamide | IV / PO / Oral suspension | Antineoplastic | Hazardous waste |
| Cyclophosphamide/Mesna (Combination) | IV | Antineoplastic | |
| Cytarabine (inj) | IV/SQ/IT | Antineoplastic | |
| Dabrafenib | PO | Antineoplastic | |
| Dacarbazine | IV | Antineoplastic | |

| Antineoplastic Hazardous Drugs | | | |
|---|--------------------------|--------------------------|-------------------------|
| Drug | Route | Class | Consensus Risk Category |
| Dactinomycin | IV | Antineoplastic | |
| Dasatinib | PO | Antineoplastic | |
| Daunorubicin | IV | Antineoplastic | Hazardous waste |
| Decitabine | IV | Antineoplastic | |
| Degarelix | SQ | GnRH receptor antagonist | |
| Docetaxel | IV | Antineoplastic | |
| Doxorubicin | IV | Antineoplastic | |
| Doxorubicin Liposomal | IV | Antineoplastic | |
| Doxorubicin / Dacarbazine (Combination) | IV | Antineoplastic | |
| Enzalutamide | PO | Antineoplastic | |
| Epirubicin | IV | Antineoplastic | |
| Eribulin | IV | Antineoplastic | |
| Erlotinib | PO | Antineoplastic | |
| Estramustine | PO | Antineoplastic | |
| Etoposide | IV/Inj given orally / PO | Antineoplastic | |
| Etoposide phosphate | IV | Antineoplastic | |
| Everolimus | PO | Antineoplastic | |
| Exemestane | PO | Antineoplastic | |
| Floxuridine | Injection | Antineoplastic | |
| Fludarabine | IV/PO | Antineoplastic | |
| Fluorouracil | IV/Topical | Antineoplastic | |
| Flutamide | PO | Antineoplastic | |
| Fulvestrant | IM | Antineoplastic | |
| Gefitinib | PO | Antineoplastic | |
| Gemcitabine | IV | Antineoplastic | |
| Gemtuzumab ozogamicin | IV | Antineoplastic | |
| Goserelin | SQ | GNRH analog | |
| Histrelin | Injection | GRH Agonist | |
| Hydroxyurea | PO / Oral suspension | Antineoplastic | |
| Idarubicin | IV | Antineoplastic | |
| Ifosfamide | IV | Antineoplastic | |
| Ifosfamide/Mesna Combination | IV | Antineoplastic | |
| Imatinib | PO | Antineoplastic | |
| Irinotecan | IV | Antineoplastic | |
| Irinotecan Liposomal | IV | Antineoplastic | |
| Ixabepilone | IV | Antineoplastic | |
| Ixazomib | PO | Antineoplastic | |
| Lapatinib | PO | Antineoplastic | |
| Letrozole | PO | Antineoplastic | |

| Antineoplastic Hazardous Drugs | | | |
|------------------------------------|--------------------------|-------------------------|-------------------------|
| Drug | Route | Class | Consensus Risk Category |
| Letrozole / Ribociclib Combination | PO | Antineoplastic | |
| Leuprolide acetate | IM | GRH Agonist | |
| Lomustine | PO | Antineoplastic | |
| Mechlorethamine | IV | Antineoplastic | |
| Megestrol Acetate | PO/Suspension | Antineoplastic | Hazardous Waste |
| Melphalan | IV / PO | Antineoplastic | |
| Mercaptopurine | PO / Oral suspension | Antineoplastic | |
| Methotrexate | IV/ IM /SQ /Topical / PO | Antineoplastic | |
| Mitomycin | IV/intravesical | Antineoplastic | Hazardous Waste |
| Mitotane | PO | Antineoplastic | |
| Mitoxantrone | IV | Antineoplastic | |
| Nelarabine | IV | Antineoplastic | |
| Nilotinib | PO | Antineoplastic | |
| Nilutamide | PO | Antineoplastic | |
| Omacetaxine | SQ | Antineoplastic | |
| Oxaliplatin | IV | Antineoplastic | |
| Paclitaxel | IV | Antineoplastic | |
| Paclitaxel protein bound | IV | Antineoplastic | |
| Panobinostat | PO | Antineoplastic | |
| Pazopanib | PO | Antineoplastic | |
| Pemetrexed | IV | Antineoplastic | |
| Pentostatin | IV | Antineoplastic | |
| Pertuzumab | IV | Antineoplastic | |
| Pomalidomide | PO | Antineoplastic | |
| Ponatinib | PO | Antineoplastic | |
| Pralatrexate | IV | Antineoplastic | |
| Procarbazine | PO | Antineoplastic | |
| Regorafenib | PO | Antineoplastic | |
| Ribociclib | PO | Antineoplastic | |
| Romidepsin | IV | Antineoplastic | |
| Sorafenib | PO | Antineoplastic | |
| Streptozocin | IV | Antineoplastic | Hazardous Waste |
| Sunitinib | PO | Antineoplastic | |
| Tamoxifen | PO | Estrogen Rec Antagonist | |
| Temozolomide | PO / Oral suspension | Antineoplastic | |
| Temsirolimus | Injection | Antineoplastic | |
| Teniposide | IV | Antineoplastic | |

| Antineoplastic Hazardous Drugs | | | |
|--|----------------------------------|-------------------------|-------------------------|
| Drug | Route | Class | Consensus Risk Category |
| Thioguanine | PO | Antineoplastic | |
| Thiotepa | IV/intravesical | Antineoplastic | |
| Topotecan (inj) | IV | Antineoplastic | |
| Toremifene | PO | Estrogen Rec Antagonist | |
| Trabectedin | IV | Antineoplastic | |
| Trametinib | PO | Antineoplastic | |
| Trastuzumab | IV | Antineoplastic | |
| Trifluridine/Tipiracil (Combo product) | PO | Antineoplastic | Hazardous Waste |
| Triptorelin | IM/SQ | GnRH agonist | |
| Valrubicin | Intravesical | Antineoplastic | |
| Vandetanib | PO | Antineoplastic | |
| Vemurafenib | PO | Antineoplastic | |
| Vinblastine sulfate | IV | Antineoplastic | |
| Vincristine sulfate | IV | Antineoplastic | |
| Vincristine/Doxorubicin (Combination) | IV | Antineoplastic | |
| Vincristine Liposomal | IV | Antineoplastic | |
| Vinorelbine tartrate | IV | Antineoplastic | |
| Vismodegib | PO | Antineoplastic | |
| Vorinostat | PO | Antineoplastic | |
| Ziv-aflibercept | IV | Antineoplastic | |
| Non-Antineoplastic Hazardous Drugs | | | |
| Drug | Route | Class | Consensus Risk Category |
| Abacavir | PO/Oral liquid | NRTI | |
| Abacavir/Dolutegravir/Lamivudine | PO | Antiretroviral combo | |
| Abacavir/Lamivudine | PO | Antiretroviral combo | |
| Abacavir/Lamivudine/Zidovudine | PO | Antiretroviral combo | |
| Alefacept | IV/IM | Immunosuppressant | |
| Apomorphine | SQ | Antiparkinsons | |
| Azathioprine | IV/PO/Oral suspension | Immunosuppressant | |
| Carbamazepine | PO/CHEW/ER/Oral suspension | Anticonvulsant | |
| Chloramphenicol | IV | Antibiotic | |
| Cidofovir | IV | Antiviral | |
| Cyclosporin | IV | Immunosuppressant | |
| Cyclosporine | PO/ IV/ Oral liquid / Ophthalmic | Immunosuppressant | |
| Deferiprone | PO/Oral liquid | Chelating agent | |

| Non-Antineoplastic Hazardous Drugs | | | |
|---|-----------------------|----------------------------|-------------------------|
| Drug | Route | Class | Consensus Risk Category |
| Desogestrel/ethynodiol | PO | Contraceptive | |
| Dexrazoxane | IV | Tissue protectant | |
| Diethylstilbestrol | PO | Non-steroid estrogen | |
| Divalproex | PO | Anticonvulsant | |
| Entecavir | PO/ Oral solution | Antiretroviral | |
| Estradiol (tablet) | PO | Hormone | |
| Estradiol / Levonorgestrel | PO | Hormone | |
| Estradiol/medroxyprogesterone | PO | Hormone | |
| Estradiol/norethindrone | PO | Hormone | |
| Estrogens, conjugated | IV/IM/Vaginal | Hormone | |
| Estrogens (conjugated)/medroxyprogesterone | PO | Hormone | |
| Estrogens (conjugated, esterified, combined w/ progestin) | PO | Hormone | |
| Estrogens (estrone, estropipate combined w/ progestin) | PO | Hormone | |
| Estropipate | PO | Hormone | |
| Ethinyl estradiol | PO | Hormone | |
| Ethinyl estradiol/drospirenone | PO | Contraceptive | |
| Ethinyl estradiol/ethynodiol | PO | Contraceptive | |
| Ethinyl estradiol/etonogestrel | PO | Contraceptive | |
| Ethinyl estradiol/ferrous fumarate/norethindrone acet. | PO | Contraceptive | |
| Ethinyl estradiol/levonorgestrel | PO | Contraceptive | |
| Ethinyl estradiol/norelgestromin | PO | Contraceptive | |
| Ethinyl estradiol/norethindrone | PO | Contraceptive | |
| Ethinyl estradiol/norethindrone acetate | PO | Contraceptive | |
| Ethinyl estradiol/norgestimate | PO | Contraceptive | |
| Ethinyl estradiol/norgestrel | PO | Contraceptive | |
| Fingolimod | PO | Biologic response modifier | |
| Fluoxymesterone | PO | Androgen | |
| Fosphenytoin | IV | Anticonvulsant | |
| Ganciclovir | IV/PO/Oral suspension | Antiviral | |
| Gefitinib (tablet) | PO | TK Inhibitor | |
| Lamivudine/Zidovudine | PO | Antiretroviral | |
| Leflunamide | PO | Anti-rheumatic | |
| Lenalidomide | PO | Immunomodulator | |
| Liraglutide | SQ | Incretin mimetic | |
| Liraglutide & Insulin degludec | SQ | Incretin mimetic/insulin | Hazardous waste |
| Medroxyprogesterone acetate | PO/IV | Hormone/ Contraceptive | |
| Methimazole | PO | Antithyroid | |

| Non-Antineoplastic Hazardous Drugs | | | |
|-------------------------------------|---|----------------------------|-------------------------|
| Drug | Route | Class | Consensus Risk Category |
| Mipomersen | Injection | Cholesterol lowering agent | |
| Mycophenolate mofetil | IV/PO/Oral suspension | Immunosuppressant | |
| Mycophenolic acid EC | PO | Immunosuppressant | |
| Nevirapine | PO/Oral suspension | NNRTI | |
| Ospemifene | PO | SERM | |
| Oxcarbazepine | PO/ER/Oral suspension | Anticonvulsant | |
| Palifermin | IV | Cell proliferant | |
| Paliperidone | PO/ Injection, long acting | Antipsychotic | |
| Phenoxybenzamine | PO | Alpha 1 blocker | |
| Phenytoin | IV/PO /Chewable / Suspension | Anticonvulsant | |
| Progesterone | PO/IM/Topical (gel) | Hormone | |
| Progestins | PO/IM/Topical (gel) | Hormone | |
| Propylthiouracil | PO | Antithyroid | |
| Raloxifene | PO | SERM | |
| Rasagiline | PO | Anti-parkinsonian | |
| Risperidone | PO/M-tab/Oral liquid /IM (microspheres) | Antipsychotic | |
| Sirolimus | PO / Oral suspension | Immunosuppressant | |
| Spironolactone | PO / Oral Suspension | Diuretic | |
| Spironolactone / Hydrochlorthiazide | PO | Diuretic | |
| Tacrolimus | IV/PO/ Topical / Oral suspension | Immunosuppressant | |
| Teriflunomide | PO | Pyrimadine synth inhibitor | |
| Thalidomide | PO | Antineoplastic | |
| Tofacitinib | PO | Antirhematic | |
| Valganciclovir | PO / Oral suspension | Antiviral | |
| Valproic acid | IV/PO/Oral liquid | Anticonvulsant | |
| Zidovudine | IV/PO / Oral solution | Antiretroviral | |

| Reproductive (Non-antineoplastic) Risk Hazardous Drugs | | | |
|--|-----------------------|----------------------------|-------------------------|
| Drug | Route | Class | Consensus Risk Category |
| Acitretin | PO | Retinoid-like | |
| Alitretinoin Top | Topical | Retinoid | Hazardous waste |
| Ambrisentan | PO | Endothelan Rec Antagonist | |
| Bosentan | PO | Endothelan Rec Antagonist | |
| Cabergoline | PO | Dopamine receptor agonist | |
| Cetorelax acetate | SQ | GRH Antagonist | |
| Choriogonadotropin | Injection | Ovulation stimulator | |
| Clindamycin/Tretinoin | Topical | Anti-acne combination | |
| Clomiphene | PO | Ovulation stimulator | |
| Clonazepam | PO/suspension | Benzodiazepine | |
| Colchicine | PO | Anti-gout | |
| Dehydroepiandrosterone (DHEA) | PO | Hormonal agent | |
| Depo-Testosterone | Injection | Androgen | |
| Diclofenac/Misoprostol | Oral | NSAID/prostaglandin | |
| Dinoprostone (insert/gel) | Top | Prostaglandin | |
| Dronedarone | PO | Antiarrhythmic | |
| Dutasteride | PO | Antiandrogen | |
| Ergonovine/methylergonovine | Injection | Oxytocics | |
| Eslicarbazepine | PO | Anticonvulsant | |
| Finasteride | PO | Alpha reductase inhibitor | |
| Fluconazole | PO/IV/Oral suspension | Anti-fungal | |
| Ganirelix acetate | SQ | GRH Antagonist | |
| Gonadotropin, chorionic | Injection | Ovulation stimulator | |
| Icatibant | IV | Bradykinin rec antagonist | |
| Isotretinoin | PO | Retinoid for acne | |
| Lomitapide | PO | Cholesterol lowering agent | |
| Macitentan | PO | Vasodilator | |
| Menotropins | IM/SQ | Ovulation stimulator | |
| Mestranol/norethindrone | PO | Contraceptive | |
| Methylergonovine | Injection | Oxytocics | |
| Methyltestosterone | PO | Androgen | |
| Mifepristone | PO | Anti-progestin | |
| Misoprostol | PO | Prostaglandin | |
| Nafarelin | Intranasal | GRH Agonist | |
| Norethindrone | PO | Contraceptive | |
| Norethindrone acetate | PO | Contraceptive | |

| Reproductive (Non-antineoplastic) Risk Hazardous Drugs | | | |
|--|---------------------|----------------------------|-------------------------|
| Drug | Route | Class | Consensus Risk Category |
| Oxytocin | IV | Oxytocics | |
| Pamidronate | IV | Bisphosphonate | |
| Paroxetine | PO | SSRI | |
| Pasireotide | Injection | Somatostatin analog | |
| Peginesatide | Injection | Erythrocyte stimulator | |
| Pentetate calcium trisodium | IV/inh | Antidote / Chelating agent | |
| Phentermine/Topiramate | Oral | Weight loss drug | |
| Plerixafor | SQ | Hematopoietic agent | |
| Ribavirin (tablet) | PO | Antiviral | |
| Ribavirin (N95 inhalation) | Inh | Antiviral | |
| Ribavirin/interferon alpha-2b recombinant | SQ | Anti-Hep C virus | |
| Riociguat | PO | Pulmonary htn medication | |
| Telavancin | IV | Antibiotic | |
| Temazepam | PO | Benzodiazepine | |
| Testosterone Topical/Injection | Top/Injection | Androgen | |
| Topiramate | PO/Oral suspension | Anticonvulsant | |
| Tretinooin (capsule, cream, gel) | Oral, Topical | Retinoid | Hazardous waste |
| Ulipristal | Oral | Contraceptive | |
| Valproate/Valproic acid | IV/ PO /Oral liquid | Anticonvulsant | |
| Vigabatrin | Oral | Anticonvulsant | |
| Voriconazole | Oral/IV/suspension | Anti-fungal | |
| Warfarin | IV/PO | Anticoagulant | Hazardous waste |
| Ziprasidone | IM/PO | Antipsychotic | |
| Zoledronic acid | IV | Biphosphonate | |
| Zonisamide | PO/Oral suspension | Anticonvulsant | |

| Hazardous Waste | |
|---|---|
| Drug | Consensus Risk Category |
| Albuterol /Ipratropium MDI Canisters | Hazardous Waste Only |
| Albuterol MDI Canisters | Hazardous Waste Only |
| Alcohol, dehydrated 98% | Hazardous Waste Only |
| Alitretinoin topical products | Reproductive (Nonantineoplastic) Risk Hazardous Waste |
| Amyl Nitrate | Hazardous Waste Only |
| Argatroban | Hazardous Waste Only |
| Arsenic trioxide | Antineoplastic Hazardous Waste, 2 methods, note well: ->Empty vials or IV bags – place in black bin -> Vials/IV bags w/ >3% remaining – return to pharmacy (DT or CC) for EHS pick up |
| Beclomethasone MDI Canisters | Hazardous Waste Only |
| Budesonide/Fomoterol MDI Canisters | Hazardous Waste Only |
| Chloral hydrate | Hazardous Waste Only |
| Chlorambucil | Antineoplastic Hazardous Waste |
| Chromium Solution (Undiluted) | Hazardous Waste Only |
| Cyclophosphamide | Antineoplastic Hazardous Waste |
| Daunorubicin | Antineoplastic Hazardous Waste |
| Fluticasone MDI Canisters | Hazardous Waste Only |
| Fluticasone/Salmeterol MDI Canisters | Hazardous Waste Only |
| Insulin aspart (all strengths/combinations) | Hazardous Waste Only |
| Insulin glargine (all strengths/combinations) | Hazardous Waste Only |
| Insulin lispro (all strengths/combinations) | Hazardous Waste Only |
| Ipratropium MDI Canisters | Hazardous Waste Only |
| Isosorbide Dinitrate Tabs | Hazardous Waste Only |
| Levalbuterol MDI cannisters | Hazardous Waste Only |
| Lindane | Hazardous Waste Only |
| Liraglutide & Insulin degludec | Non-Antineoplastic Hazardous Waste |
| Lispro Insulin | Hazardous Waste Only |
| Lopinavir-rotonavir Solution | Hazardous Waste Only |
| Mastisol adhesive | Hazardous Waste Only |
| Melphalan (inj) | Antineoplastic Hazardous Waste |

| Hazardous Waste | |
|--|---|
| Drug | Consensus Risk Category |
| Mitomycin (inj) | Antineoplastic Hazardous Waste |
| Nicotine inhalers, patches, gum and wrappers | Hazardous Waste Only |
| Nitroglycerin tabs, patches, inject, drips | Hazardous Waste Only |
| Olodaterol MDI canisters | Hazardous Waste Only |
| Oxybutynin | Hazardous Waste Only |
| Phenol Liquid | Hazardous Waste Only |
| Reserpine Tablets | Hazardous Waste Only |
| Selenium Injection Solution (Undiluted) | Hazardous Waste Only |
| Selenium Sulfide Lotion | Hazardous Waste Only |
| Silver Nitrate Sticks | Hazardous Waste Only – 2 methods, note well: <u>Unused</u> Silver Nitrate Sticks-Return to pharmacy (DT or CC) for EHS pick up <u>Used</u> Silver Nitrate Sticks – place in regular trash |
| Silver sulfadiazine topical products | Hazardous Waste Only |
| Streptozocin | Antineoplastic Hazardous Waste |
| Thimerosal (Vaccines containing) | Hazardous Waste Only |
| Tiotropium MDI Canisters (respi-mat) | Hazardous Waste Only |
| Tiotropium/Olodaterol MDI Canisters | Hazardous Waste Only |
| Trace Elements (Undiluted) | Hazardous Waste Only |
| Tretinoin topical products | Reproductive (Nonantineoplastic) Risk Hazardous Waste |
| Trichloroacetic acid | Hazardous Waste Only |
| Trifluridine/Tipiracil | Antineoplastic Hazardous Waste |
| Warfarin | Reproductive (Nonantineoplastic) Risk Hazardous Waste |